Printer Friendly

TARGET THERAPEUTICS CEO REVIEWS RECENT DEVELOPMENTS AT H&Q; UPDATE ON FISCAL 1994 AND PROJECTED THIRD QUARTER EARNINGS

 SAN FRANCISCO, Jan. 11 /PRNewswire/ -- In remarks made at the Hambrecht & Quist 12th Annual Life Sciences Conference yesterday, Target Therapeutics (NASDAQ: TGET) President and Chief Executive Officer Gary R. Bang reported strong progress during fiscal 1994, including estimated third quarter sales and earnings, and gave an update on changes to the Guglielmi Detachable Coil (GDC) system.
 Projected Q3 FY94 Earnings Higher Than Estimates
 Bang reported that earnings for Target's fiscal 1994 third quarter (ended Dec. 31, 1993) will reflect increased revenues of approximately $9.3 million, up 27% from $7.3 million in the comparable prior-year period, due to a rate of sales growth in excess of Wall Street expectations.
 "We believe earnings per share for the quarter will come in around 20 to 23 cents, compared with recent Street predictions ranging from 13 to 17 cents per share," said Bang. "Impressive U.S. and international sales performance across product lines, and lower-than-anticipated expense growth have both contributed to a strong quarter."
 In particular, sales of the FasTRACKER(TM) infusion catheter with Hydrolene(TM) have been strong since its introduction to the U.S. market in August 1993. The FasTRACKER(TM) builds on the innovative design characteristics of Target's Tracker(R) microcatheter products, and is distinguished by its 2-micron-thick chemically bonded hydrophilic polymer, Hydrolene(TM). As reference, red blood cells measure approximately 8 microns across, and the width of a human hair is approximately 40 microns.
 Target's projected earnings per share of 20 to 23 cents represent an approximate increase of 55% to 77% over prior-year third quarter earnings. The company intends to issue third quarter earnings on or about Jan. 25, 1994.
 Progress with the GDC
 Bang reported continued progress with the modified GDC system, announcing that an Investigational Device Exemption (IDE) supplement for the modified GDC system has been submitted to the Food and Drug Administration (FDA).
 "Target continues to move forward with the modified GDC system, maintaining open lines of communication with physicians and FDA," said Bang. "We are especially pleased with the strong ongoing support demonstrated by physicians."
 Treatment with the original GDC system continues to be left to the discretion of physicians with patients suffering from high-risk or inoperable cerebral aneurysms who have no other acceptable therapeutic alternatives.
 Experts Focus on Stroke
 Bang also discussed a recent focus in the medical community on stroke, evidenced by a recent surge in seminars and formalized education and treatment programs at universities and hospitals nationwide.
 "This growing interest in stroke, specifically in the six-hour window of opportunity for treatment following a stroke, has brought together neurologists, neurosurgeons and interventional neuroradiologists from across the nation," said Bang. "Such a combination of multiple disciplines often results in optimum therapies that capitalize on the most advanced technologies, procedures and devices."
 About Target Therapeutics
 Founded in 1985, Target Therapeutics Inc. develops, manufactures and markets innovative, highly specialized disposable micro-catheters, guidewires, micro-coils and angioplasty products. These therapeutic devices are used in minimally invasive non-surgical procedures to reach disease sites throughout the body via the circulatory system. Target's products allow highly targeted treatment of the diseased, ruptured or blocked vessels of the brain responsible for stroke, as well as other disease sites in the body that are accessible through small blood vessels.
 -0- 1/11/94
 /CONTACT: analysts, Larry Tannenbaum, vice president of finance and administration and chief financial officer of Target Therapeutics, 510-440-7700; or media, Bruce Voss of Edelman Public Relations, 415-433-5381, for Target Therapeutics/
 (TGET)


CO: Target Therapeutics Inc. ST: California IN: MTC SU: ERP

RB-LW -- SF001 -- 0803 01/11/94 07:01 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 11, 1994
Words:592
Previous Article:AGOURON PHARMACEUTICALS EXPANDS CLINICAL TESTING OF SECOND CANCER DRUG INTO UNITED STATES
Next Article:ROBUST FAX STORE & FORWARD AND FAX BROADCAST VIA NETFAX SWITCH 400 BY OAZ COMMUNICATIONS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters